DXDonglin Xia

Donglin Xia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Donglin Xia has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PBP‐Functionalized Platelets Enable Targeted IL‐10 Delivery for the Attenuation of Atherosclerosis and Splenic Inflammation

    by Qiuyan Yu, Yan Feng, Hanrui Sun, Weiping Zhou, Haoliang Ni, Yangfeng Chen, Juan Zhao, Xiayu Ren, Donglin Xia, Weijing Wang, et al.

    Atherosclerosis is a chronic inflammatory disease of the arterial wall and a major cause of cardiovascular morbidity and mortality worldwide. The anti‐inflammatory cytokine interleukin‐10 (IL‐10) plays a critical role in regulating vascular inflammation; however, its therapeutic application is limited by a short half‐life, rapid systemic clearance, and insufficient accumulation at inflammatory sites. Here, we developed a platelet‐based targeted delivery system for IL‐10 (IL‐10@PLT‐PBP) by encapsulating IL‐10 into rat‐derived platelets and functionalizing the platelet surface with a P‐selectin binding peptide (PBP). This modification facilitates selective targeting of activated endothelium within atherosclerotic lesions, where P‐selectin is highly expressed during vascular inflammation. In vitro and in vivo studies demonstrated that IL‐10@PLT‐PBP efficiently accumulated in atherosclerotic plaques and enabled localized IL‐10 release. In high‐fat diet (HFD)‐fed ApoE − / − mice, IL‐10@PLT‐PBP exhibited enhanced plaque targeting and sustained IL‐10 delivery compared with free IL‐10 and nontargeted IL‐10@PLT ( p < 0.01). Importantly, targeted IL‐10 delivery significantly reduced the infiltration of proinflammatory myeloid cells and T cells within atherosclerotic lesions, whereas nontargeted IL‐10@PLT showed limited therapeutic effects. Moreover, IL‐10@PLT‐PBP markedly decreased iNOS + proinflammatory macrophage accumulation in both atherosclerotic plaques and the adjacent vascular wall. Notably, treatment with IL‐10@PLT‐PBP increased the proportion of IL‐10‐producing splenic leukocytes (CD45 + IL‐10 + , p = 0.0177), accompanied by reduced splenic inflammatory activation, suggesting systemic immune modulation beyond local plaque targeting. Collectively, these findings demonstrate that PBP‐functionalized platelet‐mediated IL‐10 delivery effectively suppresses local vascular inflammation and regulates splenic immune responses, providing a targeted immunotherapeutic strategy for atherosclerosis and potentially other inflammation‐associated diseases.

  • Open Access

    Biodegradable 3D Injectable Amino Acid Hydrogels Delivering Immune Adjuvant for Enhancing Immunotherapy in Colon Cancer

    by Mengfei Yin, Ling Mao, Xunlei Zhang, Jiali Ji, Li Song, Qingxia Ma, Donglin Xia, Lei Yang

    Cancer immunotherapy using toll‐like receptor agonists (R837) has been extensively investigated and demonstrates potential as an effective adjuvant. Due to the potential for severe side effects associated with R837, the subcutaneous injection of a hydrogel scaffold may enhance its efficacy. Herein, we propose a biodegradable 3D injectable scaffold as an injectable delivery carrier for R837 (R837@Gel), to control the release rate of R837 and be friendly to subcutaneous tissue. Biodegradable 3D injectable amino acid hydrogels were constructed by catalase effect during Fmoc‐Phe and Phe2 substrates. After subcutaneous injection, R837@Gel formed a hydrogel‐like component, provided adequate 3D support, and released R837 in order owing to the decomposition of amino acids. Effective CD4+ and CD8+ T‐cell responses were observed, promoted by R837@Gel (p < 0.001). The amino acid hydrogel scaffold exhibited a favorable safety profile and could be degraded successfully. The biodegradable 3D injectable amino acid hydrogels prolonged the action duration of R837 and markedly enhanced the efficacy of PD‐1. The 3D amino acid hydrogel scaffold encapsulating R837 in combination with immune checkpoint blockade represents a potent strategy for enhancing antitumor immunotherapy while mitigating systemic toxicity concerns. Moreover, controlled drug administration via subdermal implants has significant potential for reducing the compliance burden associated with frequent dosing. The combination of biocompatibility, ease of modification, and the ability to create a 3D microenvironment makes amino acid hydrogels a valuable tool in the field of regenerative medicine and tissue engineering.


  • Open Access

    Editorial: Environmentally-responsive biomaterials for major diseases treatment

    by Yan Zhao, Donglin Xia, Yao Luo

    Environmentally-responsive biomaterials are a novel class of materials that undergo structural or functional changes by altering their internal atom arrangement in response to environmental stimuli. These stimuli include endogenous disease microenvironments, such as the acidic pH of tumor microenvironments or elevated enzymatic activity in inflamed tissues, external physical triggers, such as temperature, light, ultrasound, or magnetic fields, and the combinations of these stimuli (Mura et al., 2013, Chen et al., 2022, Zhu et al., 2023). A variety of environmentally-responsive biomaterials have been developed to date, including DNA nanostructures (Zhao et al., 2023, Li et al., 2024, Zhao et al., 2024c, Zhao et al., 2021, Liu et al., 2023, Ji et al., 2022), hydrogels (Ma et al., 2023, Zhao et al., 2024b, Guo et al., 2023), nanomicelles (Wang et al., 2024, Uthaman et al., 2024, Wang et al., 2023) and biomembranes-based materials (Su et al., 2022). Those environmentally-responsive biomaterials achieve the delivery and release of therapeutics with precise spatial and temporal control, minimizing off-target effects and maximizing treatment efficacy in vitro and in vivo (Xue et al., 2023, Cui et al., 2024, Wei et al., 2011, Xia et al., 2019).For the treatment of clinical diseases, one of the primary advantages of environmentally-responsive biomaterials is their ability to provide targeted and on-demand therapeutic solutions. By leveraging the unique pathological microenvironments of diseases or physical stimuli, these materials enhance the selectivity and efficiency of treatments. Additionally, their adaptability reduces the need for external intervention, improving patient compliance and reducing systemic toxicity. Applications of environmentally-responsive biomaterials span across major disease treatments (Zhao et al., 2024a, Guo et al., 2016, Duan et al., 2022, Xia et al., 2020), including cancer, diabetes, cardiovascular disorders. For example, pH-sensitive hydrogels are used for localized drug delivery in cancer therapy (Lin et al., 2025), while thrombin-responsive DNA nanomachines aid in precise delivery and accurate dosing of tissue plasminogen activator release for thrombolytic therapy (Yin et al., 2024). Furthermore, advancements in this field are paving the way for tissue engineering (Zhang et al., 2018), regenerative medicine, and autoimmune diseases (Shodeinde et al., 2020), driving a paradigm shift in modern healthcare (Zhang et al., 2015). In summary, environmentally responsive biomaterials embody the intersection of material science and medicine, offering innovative and sustainable solutions to some of the most pressing challenges in disease treatment. This Research Topic collected excellent works on the "Environmentally-Responsive Biomaterials for Major Diseases Treatment", and a total of 9 articles from 38 authors were accepted. The contributions have deepened the understanding of this topic from perspectives such as the development of environmentally-responsive biomaterials and the strategies for utilizing environmental signals in clinical treatment. This research topic can be broadly divided into the following three subfields.External stimuli, such as temperature, light, ultrasound, and magnetic fields, enable precise, controllable activation of biomaterials, allowing for non-invasive and on-demand therapeutic interventions. In our research topic, Zhang et al. developed an optogenetic-based mitochondrial aggregation system (Opto-MitoA) based on a CRY2clust/CIBN light-sensitive module. Through rapidly controlling mitochondrial aggregation in cells upon blue light illumination, this system could increase the energy-generating function of mitochondria and alleviate niclosamide-caused cell dysfunction. Chen et al. synthesized albumin-loaded Tanshinone IIA and near-infrared photothermal agent IR780 nanoparticles for managing chronic and infected wounds. The release of Tanshinone IIA was improved under laser irradiation, thus realizing enhanced wound healing. Shang et al. reviewed polydopamine-coated metal-organic frameworks (MOFs@PDA) multifunctional nanomaterial, highlighting their potential in cancer therapy. By leveraging strong photothermal responsiveness of polydopamine, MOFs@PDA enable controlled drug release triggered by near-infrared light, enhancing therapeutic precision and minimizing side effects in cancer treatment.Endogenous disease microenvironments, including acidic pH, hypoxia, and enzymatic activity, provide intrinsic biological triggers that enable biomaterials to achieve site-specific responses and targeted drug release. Tan et al. designed GSH-responsive nanomicelles that release glucose transporter 1 (GLUT1) inhibitor to block mononuclear phagocyte system (MPS) uptake, significantly improving tumor treatment. Xiao et al. emphasized the critical role of rebuilding the myocardial microenvironment in mesenchymal stem cells (MSCs)-based myocardial regeneration. This review highlights the strategies for promoting angiogenesis to improve MSCs survival and function in the treatment of ischemic heart disease. Ma et al. developed a multiplexed microfluidic immunoassay chip based on nanozyme technology for detecting eight respiratory viruses, demonstrating its application in sensing endogenous microenvironments through virus-specific antigen detection. Wang et al. reviewed reactive oxygen species (ROS)-responsive biomaterials for Myocardial ischemia-reperfusion injury (MIRI) treatment as the ROS microenvironment. They systematically summarized the fabrication strategies and therapeutic platforms of ROS-responsive biomaterials, paving the way for their clinical translation. Han et al. utilized nanodiamonds as carriers to deliver MicroRNA-7 into dopaminergic neurons for the treatment of Parkinson's disease. They used the nanodiamonds & MicroRNA-7 complex (N-7) to inhibit the expression of αsynuclein, reduce oxidative stress and restore dopamine levels effectively.


  • Open Access

    Nano-Oncologic Vaccine for Boosting Cancer Immunotherapy: The Horizons in Cancer Treatment

    by Chao Chen, Yue Xu, Hui Meng, Hongyi Bao, Yong Hu, Chunjian Li, Donglin Xia

    Nano-oncologic vaccines represent a groundbreaking approach in the field of cancer immunotherapy, leveraging the unique advantages of nanotechnology to enhance the effectiveness and specificity of cancer treatments. These vaccines utilize nanoscale carriers to deliver tumor-associated antigens and immunostimulatory adjuvants, facilitating targeted immune activation and promoting robust antitumor responses. By improving antigen presentation and localizing immune activation within the tumor microenvironment, nano-oncologic vaccines can significantly increase the efficacy of cancer immunotherapy, particularly when combined with other treatment modalities. This review highlights the mechanisms through which nano-oncologic vaccines operate, their potential to overcome existing limitations in cancer treatment, and ongoing advancements in design. Additionally, it discusses the targeted delivery approach, such as EPR effects, pH response, ultrasonic response, and magnetic response. The combination therapy effects with photothermal therapy, radiotherapy, or immune checkpoint inhibitors are also discussed. Overall, nano-oncologic vaccines hold great promise for changing the landscape of cancer treatment and advancing personalized medicine, paving the way for more effective therapeutic strategies tailored to individual patient needs.


  • Enhancing Chemotherapy Efficacy via an Autologous Erythrocyte-Anchoring Strategy with a Closed-System Drug-Transfer Device

    by Lingzi Feng, Xiangqian Wang, Ziyi Gao, Yuqing Tong, Xiaopeng Yuan, Ting Wu, Donglin Xia, Yong Hu

    Chemotherapeutic drugs often fail to localize efficiently to tumors when administered intravenously, causing off-target effects. This study proposes an autologous erythrocyte (ER)-anchoring strategy to improve chemotherapy efficacy and reduce side effects. Utilizing a modified hemodialysis instrument, a closed-system drug-transfer device was developed for autologous ER procurement and immunogenicity mitigation. Doxorubicin (DOX) and indocyanine green (ICG) were encapsulated in autologous ERs and then modified with DSPE-PEG-FA. The final product, DOX-ICG@ER-D, was reintroduced into circulation to enhance chemotherapy. These obtained DOX-ICG@ER-D showed good stability, minimal cardiotoxicity, and extended circulation time. Compared to free DOX, DOX-ICG@ER-D had a higher accumulation of DOX in hepatocellular carcinoma and the release of DOX could be controlled by laser irradiation. Tumor-bearing rats treated by these DOX-ICG@ER-D demonstrated improved antitumor efficacy and reduced cardiotoxicity. Thus, this autologous ER-anchoring strategy offers a promising alternative to intravenous chemotherapy in the clinic.


  • Open Access

    A Platelet-Powered Drug Delivery System for Enhancing Chemotherapy Efficacy for Liver Cancer Using the Trojan Horse Strategy

    by Hao Huang, Xiaoping Wang, Ziqing Gao, Hongyi Bao, Xiaopeng Yuan, Chao Chen, Donglin Xia, Xiangqian Wang

    Optimizing the delivery and penetration of nano-sized drugs within liver cancer sites, along with remodeling the tumor microenvironment, is crucial for enhancing the efficacy of chemotherapeutic agents. For this study, a platelet (PLT)-mediated nanodrug delivery system (DASA+ATO@PLT) was developed to improve the effectiveness of chemotherapy. This system delivers nano-sized dasatinib and atovaquone specifically to liver tumor sites and facilitates intra-tumoral permeation upon release. Through JC-1, immunohistochemistry, and DNA damage analyses, the therapeutic effect of DASA+ATO@PLT was assessed. In vitro simulation and intravital imaging were carried out to determine the accumulation of dasatinib and atovaquone in liver tumor sites. The experiment demonstrated the accumulation of dasatinib and atovaquone in tumor sites, followed by deep permeation in the tumor microenvironment with the assistance of PLTs, while simultaneously revealing the ability of DASA+ATO@PLT to remodel the liver cancer microenvironment (overcoming hypoxia) and enhance chemotherapeutic efficacy. This system utilizes the natural tumor recognition ability of PLTs and enhances the chemo-immunotherapeutic effect through targeted delivery of nano-chemotherapeutic drugs to the tumor, resulting in effective accumulation and infiltration. The PLT-mediated nanodrug delivery system serves as a “Trojan horse” to carry therapeutic drugs as cargo and deliver them to target cells, leading to favorable outcomes.


  • Open Access

    Engineering tumor-oxygenated nanomaterials: advancing photodynamic therapy for cancer treatment

    by Tingting Zuo, Xiaodie Li, Xuan Ma, Ye Zhang, Xueru Li, Xuehai Fan, Mingze Gao, Donglin Xia, Huijun Cheng

    Photodynamic therapy (PDT), a promising treatment modality, employs photosensitizers to generate cytotoxic reactive oxygen species (ROS) within localized tumor regions. This technique involves administering a photosensitizer followed by light activation in the presence of oxygen (O2), resulting in cytotoxic ROS production. PDT’s spatiotemporal selectivity, minimally invasive nature, and compatibility with other treatment modalities make it a compelling therapeutic approach. However, hypoxic tumor microenvironment (TME) poses a significant challenge to conventional PDT. To overcome this hurdle, various strategies have been devised, including in-situ O2 generation, targeted O2 delivery, tumor vasculature normalization, modulation of mitochondrial respiration, and photocatalytic O2 generation. This review aims to provide a comprehensive overview of recent developments in designing tumor-oxygenated nanomaterials to enhance PDT efficacy. Furthermore, we delineate ongoing challenges and propose strategies to improve PDT’s clinical impact in cancer treatment.


  • Open Access

    Platelets camouflaged nanovehicle improved bladder cancer immunotherapy by triggering pyroptosis

    by Jiale Tian, Mingde Gao, Jinfeng Zhu, Haifei Xu, Hao Ji, Donglin Xia, Xiaolin Wang

    The regulation of immunosuppressive microenvironments in tumors through targeted drug delivery shows promise for immunochemotherapy in bladder cancer. Drawing inspiration from stealth tactics, a nano-vehicle camouflaged with platelets (PLTs) was developed to enable precise delivery and trigger pyroptosis for tumor immunotherapy.


  • Open Access

    Platelets as delivery vehicles for targeted enrichment of NO· to cerebral glioma for magnetic resonance imaging

    by Yuchen Ding, Min Ge, Chao Zhang, Juncheng Yu, Donglin Xia, Jian He, Zhongzheng Jia

    Using a magnetic resonance imaging (MRI) contrast agent, MRI has made substantial contributions to glioma diagnosis. Metal-free MRI agents, such as the nano free radical nitric oxide (NO·) micelle, can overcome the inherent toxicity of metal-based agents in certain patient populations. However, the low spatial resolution of nano NO· micelle in MRI limits its clinical development. In this study, we pretreated platelets (PLTs) and loaded them with nano NO· micelles to synthesize NO·@PLT, which can overcome the low contrast and poor in vivo stability of nitroxide-based MRI contrast agents. The PLTs can serve as potential drug carriers for targeting and delivering nano NO· micelles to gliomas and thus increase the contrast in T1-weighted imaging (T1WI) of MRI. This drug carrier system uses the unique tumor-targeting ability of PLTs and takes advantage of the high signal presentation of steady nano NO· micelles in T1WI, thereby ultimately achieving signal amplification of glioma in T1WI. With the effect of PLTs-tumor cell adhesion, NO·@PLT has per-nitroxide transverse relativities of approximately 2-fold greater than those of free NO· particles. These features allow a sufficient NO·@PLT concentration to accumulate in murine subcutaneous glioma tumors up from 5 min to 2.5 h (optimum at 1.5 h) after systemic administration. This results in MRI contrast comparable to that of metal-based agents. This study established a promising metal-free MRI contrast agent, NO·@PLT, for glioma diagnosis, because it has superior spatial resolution owing to its high glioma-targeting ability and has significant translational implications in the clinic.